Gut microbiota and gut-kidney axis in kidney diseases: therapeutic potential and perspectives of natural products
Qianwei Wang, Jiahe Zhang, Ruiyan Chen, Junyan Song, Jinye Lv, Zhicheng Zhou, Lijuan Dai · 2026
Read Gut microbiota and gut-kidney axis in kidney diseases: therapeutic potential and perspectives of natural products by Qianwei Wang, Jiahe Zhang, Ruiyan Chen, Junyan Song, Jinye Lv, Zhicheng Zhou, Lijuan Dai (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13473280.txt.
Description
Wang and colleagues reviewed in 2026 how gut microbe imbalance drives chronic kidney disease progression. The result is a build-up of uremic toxins, poisons normally cleared by kidneys, and a loss of protective gut products such as short-chain fatty acids. The review maps the pathways involved and compares several kidney disease types.
Toxins and missing protectors jointly trigger kidney inflammation and scarring through many signalling routes, including oxidative stress and inflammasome activation. The same gut-kidney axis appears in diabetic kidney disease, lupus nephritis, IgA nephropathy, and others, with disease-specific twists. The authors organise these shared and unique mechanisms into one framework. Such a map, they argue, points to shared drug targets across kidney diseases. It also supports gut-directed treatments, such as diet, probiotics, or toxin binders, as adjuncts to kidney care.
Catalog record
| CREATOR | Qianwei Wang, Jiahe Zhang, Ruiyan Chen, Junyan Song, Jinye Lv, Zhicheng Zhou, Lijuan Dai |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 110 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |